Merck to Highlight Data at ESMO 2022 with Potential for Transformative Impact on Cancer Patients

• Late-breaking data highlight 5-year survival results from Phase II study of the investigational IAP inhibitor xevinapant in the curative setting of unresected LA SCCHN • Initial results of Pha…